A phase I/II study of crizotinib in combination with another mTOR inhibitor, temsirolimus, in relapsed or refractory neuroblastoma with ALK or MET aberrations is currently ongoing, although unexpected toxicity caused by temsirolimus was detected (EUCTR2015-005437-53). This evidence concerns the gene MET and neuroblastoma.